Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EEF2K | O00418 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770442 | 0.84 | POLB (1.00) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL17324712 | 0.84 | POLB (0.74) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL16144859 | 0.82 | MAPT (0.72) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL24405748 | 0.82 | POLB (0.96) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL23062881 | 0.80 | POLB (0.93) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL21836678 | 0.79 | POLB (0.50) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL19997308 | 0.79 | POLB (0.68) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL24405744 | 0.79 | POLB (0.68) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL17321396 | 0.79 | POLB (0.68) | POLBMAPTTDP1L3MBTL1GAA | |
| SCHEMBL28268497 | 0.72 | POLB (0.43) | POLBMAPTTDP1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1735622-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005116653-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | GPR119, GCGR, GLP1R | POLB 4818/4885MAPT 4141/4885TDP1 3456/4885 |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | GPR119, GCGR, GLP1R | POLB 4818/4885MAPT 4141/4885TDP1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.